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Background/Aims: The distribution of blood lipids, glucose 
and their determinants in thalassemic patients with chronic 
hepatitis C virus (HCV) infection has rarely been investigated. 
Thus, we aimed to investigate the relationship between both 
liver histologic ﬁ  ndings and viral markers and serum lipids in 
thalassemic patients chronically infected with HCV. Methods: 
We enrolled 280 polytransfused thalassemic patients with 
chronic hepatitis C. HCV viral load was determined using the 
Amplicor test. Genotyping was performed using genotype 
speciﬁ  c primers. Fasting serum lipid, glucose, ferritin and liv-
er function enzyme concentrations were measured. A modi-
ﬁ  ed Knodell scoring system was used to stage liver ﬁ  brosis 
and to grade necroinﬂ  ammatory activity. Perls’ staining was 
used to assess hepatic siderosis. Results: Just one subject 
had total cholesterol >200 mg/dL, and 7% had triglycerides 
>150 mg/dL. The mean high-density lipoprotein cholesterol 
(HDL-C) and glucose levels were 37 and 104 (97-111) mg/
dL, respectively. Viral markers, liver histological ﬁ  ndings and 
aminotransferase activity were not associated with serum 
lipid levels. Serum triglycerides, total cholesterol and ferritin 
were independent risk factors for impaired glucose tolerance 
or diabetes in these patients. Conclusions: The majority of 
the patients had blood lipid levels (with the exception of HDL) 
within the deﬁ  ned normal range; viral and liver histological 
factors do not appear to play a significant role in changing 
the levels of serum lipids or glucose in these patients. (Gut 
Liver 2011;5:348-355)
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INTRODUCTION
Hepatitis C is a major health problem in the world,
1 for which 
thalassemia patients are at a higher risk.
2 Metabolic syndrome is 
a risk factor for progression of liver diseases as well. As the liver 
is the main determinant of serum lipoprotein synthesis and lipid 
metabolism, chronic liver diseases are often accompanied with 
an impaired lipid metabolism.
3 The relation between low levels 
of serum cholesterol, particularly low-density lipoprotein cho-
lesterol (LDL-C) and severity of liver disease has previously been 
described.
4 Lower total cholesterol and LDL-C levels were also 
described in hepatitis C virus (HCV)-infected patients.
5,6 Total se-
rum cholesterol and LDL-C have even been proposed to be pre-
dictors of response to interferon in HCV infected patients.
7 Fur-
thermore, it was determined that patients with chronic hepatitis 
C had lower total cholesterol levels in comparison with patients 
chronically infected with hepatitis B.
8 An association between 
HCV infection and lipid metabolism has been described as well. 
Bonding of HCV to VLDL or LDL could facilitate its entry via the 
LDL receptor.
9-11 These findings suggest that plasma lipids play 
an important role in the pathogenesis of HCV infection. Major 
beta-thalassemic patients are the most affected group of pa-
tients chronically infected with HCV. It is well known that beta-
thalassemia is associated with changes in plasma lipids. A low 
total cholesterol levels caused by a significant decrease in both 
LDL-C and high-density lipoprotein cholesterol (HDL-C) have 
been described previously in beta-thalassemia,
12 but findings for 
triglycerides were heterogeneous.
13,14 In spite of the possible role 
of serum lipids in pathogenesis of HCV infection and implica-
tion of liver disease caused by hypertransfusion in thalassemic 
patients, data regarding the distribution of blood lipids among 
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Therefore, in this study we aimed to investigate the distribution 
of serum lipids in beta-thalassemic patients with chronic HCV 
infection, and to determine if there are any correlations between 
serum lipid levels and viral load, HCV genotype, liver histology 
and serum iron.
MATERIALS AND METHODS 
1. Study design
This study was designed as an observational study to investi-
gate lipid and glucose levels and their relation with viral mark-
ers and liver histologic findings in 280 HCV infected major-
thalassemic patients.
2. Patients 
From a total of three hundred thalassemia patients with es-
tablished diagnosis of chronic HCV (positive polymerase chain 
reaction [PCR] for the last 6 months and liver histologic pattern 
of chronic hepatitis), 280 were enrolled in the present study. 
Twenty patients refused to participate or went to other centers 
to start treatment. Among all patients, 269 (96.1%) were major 
thalassemic patients receiving regular blood transfusions at 2- 
to 4-week intervals to maintain the level of hemoglobin at 10-
13 g/dL along with regular therapy with deferoxamine while 11 
(3.9%) had thalassemia-intermedia and received hydroxyurea 
and blood transfusion at long intervals. Informed consent has 
been obtained from patients at registration time. Sixty-seven 
subjects with previous liver biopsies performed more than four 
years ago refused to undergo another liver biopsy. Thus, their 
liver histologic findings were considered missing. 
3. Laboratory assessment 
Serum lipid and glucose concentration were determined after 
an overnight fast of 12 and 9 hours respectively. Alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), and alpha-fetoprotein (AFP) were detected 
using ELISA. Serum ferritin concentration was measured by 
applying IRMA. Triglyceride, total cholesterol, HDL-C, and 
LDL-C were measured enzymatically with commercial kits and 
automated analyzer. LDL-C was calculated using the Friedwald 
formula: (total cholesterol)-(HDL-C)-1/5(triglycerides).
15 The 
body mass index (BMI) was calculated in accordance with the 
formula of weight (kg) divided by height
2 (m
2).
16
4. Deﬁ  nitions 
Subjects with a previously established diagnosis of diabetes, 
currently taking any form of insulin injections or hypoglyce-
mic drugs and/or fasting blood glucose level >126 mg/dL were 
categorized as diabetes and > 110 mg/dL as significant enough 
insulin resistance (impaired glucose tolerance). As well as fast-
ing blood glucose, the cut off point for triglyceride, total cho-
lesterol was set at 150 and 200 mg/dL accordingly, with respect 
to World Health Organization (WHO) definition of metabolic 
syndrome. HDL-C <40 for males and <50 for females were also 
considered low. It is noteworthy that none of our patients were 
taking lipid lowering agents. Fasting blood glucose was above 
110 mg/dL in all diabetic patients. 
5. Histologic evaluation
All subjects underwent percutaneous liver biopsy by Meng-
hini needles. Each biopsy specimen was evaluated according 
to the modified Knodell score grading and staging system. A 
scale of 0-18 (modified HAI grading) was applied for grading of 
necroinflammatory activity and a scale of 0-6 (modified stag-
ing) was applied for staging of liver fibrosis and architectural 
disturbances. Then, staging and grading of liver damage were 
categorized into three levels of mild, moderate and severe. 0-6 
for grading and 0-2 for staging were designated as mild, 7-12 
and 3-4 as moderate and 13-18 and 5-6 as severe. Perls’ stain-
ing with score of 0-4 was applied to assess hepatic siderosis. 0-2 
was designated as mild, 3 as moderate and 4 as severe.
6. RNA extraction, cDNA synthesis, and PCR procedure
All PCR procedures and genotyping were performed as de-
scribed previously.
17
7. Statistical analysis 
Continuous variables are presented as mean values with 95% 
confidence interval. However, qualitative and discrete variables 
are presented as absolute and relative frequencies in the form 
of percentage. Chi-square test was applied to assess associations 
between categorical variables. Because of great sample size and 
power, comparisons between continuous and categorical vari-
ables were performed by Student’s t-test and one-way ANOVA 
regardless of considering normal distribution or homogeneity 
of variances. Correlations between lipids levels and age, liver 
enzymes, ferritin, glucose, viral load, and BMI were evaluated 
by the calculation of Pearson’s correlation coefficient. All com-
putations were carried out using SPSS version 16.0 (SPSS Inc., 
Chicago, IL, USA) while the graphs were provided by Stata SE 
version 8.0 (Stata Co., College Station, TX, USA). The probabil-
ity value (p) <0.05 was regarded statistically significant.
RESULTS 
1. Patients’ demographic and clinical characteristics 
Table 1 has summarized our subjects’ demographic and base-
line clinical characteristics. The mean age of our patients was 
24 years (ranging from 11 to 54) and 59% of them were male. 
Only 2 patients (0.7%) had received their first transfusion after 
1996, the year in which anti-HCV screening was established in 
Iran. 183 (65%) of subjects were splenectomized with mean age 
of 13 years at the time of procedure. The most frequent HCV 
genotypes were genotype 1 (57%) followed by 3 (35%). Fifty-350  Gut and Liver, Vol. 5, No. 3, September 2011
three out of 280 subjects (24%) had severe liver fibrosis and 9 
subjects (4%) had severe necroinflammatory. 21.1% of subjects 
had normal serum ALT level.
2. Blood lipids and glucose distribution
The mean values of the investigated blood lipids and glucose 
are presented in Table 2. Furthermore, Fig. 1 illustrates the dis-
tribution of total, HDL and LDL cholesterol, triglyceride and glu-
cose levels. Mean total cholesterol, LDL, triglyceride and glucose 
varied within normal values (<200 mg/dL for total and LDL-C, 
150 mg/dL for triglyceride, and 110 mg/dL for glucose). In addi-
tion, just one of the participants had total and HDL-cholesterol 
levels above 200 mg/dL and only 7% of subjects had higher 
than 150 mg/dL triglyceride. In contrast to above results, 151 
(72%) of our subjects had low HDL-C levels (<40 mg/dL for men 
and <50 mg/dL for women). In this study, 50% of men and 65% 
of women with normal total cholesterol levels (i.e., <200 mg/
dL) had lower than 40 and 50 mg/dL HDL-C levels, respectively. 
Mean triglyceride was also low (108 mg/dL), and 12% of men 
and 18% of women had triglyceride levels higher than 150 mg/
dL. Finally, mean LDL-C level was also low (51 mg/dL) and only 
one participant had LDL-C level higher than 200 mg/dL. 
Thirty-nine subjects (14%) had previously established diagno-
sis of diabetes mellitus (15 males and 24 females) and 31 (79%) 
of them were taking anti-hyperglycemic agents. We have found 
another 9 subjects with impaired glucose tolerance (>110 mg/
dL). Mean serum glucose level was 104 mg/dL (97-111) that 
varied in border line and in range of impaired fasting glucose 
tolerance.
It is known that age is a factor that correlates well with blood 
Table 1. Baseline Characteristics of the Patients
Patients’ characteristics  Value
Sex
  Male, n (%) 165 (59)ɹ
  Female, n (%) 115 (41)ɹ
First blood transfusion 
  After 1996, n (%) 2 (0.7)ɹ
  Before 1996, n (%) 278 (99.3)ɹ
Total no. of transfusions 
  ≥400 135 (62)ɹ
  <400   84 (38)ɹ
  Unavailable   61 (28)ɹ
History of splenectomy
  Yes, n (%) 183 (65)ɹ
  No, n (%) 97 (35)ɹ
Mean age  24 (23-25)
Mean age at time of splenectomy  13 (12-14)
Mean no. of transfusion  393 (374-413)
ALT, U/L 91 (82-100)
  Normal (<40 U/L) 59 (21.1)ɹ
  >2 folds increased n (%) 131 (46.8) ɹ
AST, U/L 74 (67-82)
  Normal (<40 U/L)  72 (25.7)ɹ
  >2 folds increased n (%)  89 (31.8)ɹ
ALP, U/L 310 (282-338)
  Normal (<306 UL/L) n (%) 156 (55.7)ɹ
AFP, ng/L 3.1 (2.4-3.7)
  >10 ng/mL n (%) 10 (3.6)ɹ
Serum ferritin, ng/L 2,014 (1,797-2,231)
Log10 serum HCV-RNA copy/mL 5.5 (5.4-5.6)
  Log10 serum HCV-RNA>6 copy/mL, n (%)  63 (22.5)ɹ
Genotype 
  Genotype 1, n (%) 160 (57)ɹ
  Genotype 2, n (%)   3 (1)ɹ
  Genotype 3, n (%)   98 (35)ɹ
  Mixed genotype, n (%)   12 (4.3)ɹ
  Untypable, n (%)  7 (2.5)ɹ
Stage of liver fibrosis
  Mild, n (%)   63 (30)ɹ
  Moderate, n (%) 102 (49)ɹ
  Severe, n (%)   53 (24)ɹ
Grade of necroinflammatory activity 
  Mild, n (%)  128 (60) ɹ
  Moderate, n (%)   76 (36)ɹ
  Severe, n (%)   9 (4)ɹ
ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
ALP, alkaline phosphatase; AFP, alpha-fetoprotein; HCV, hepatitis C 
virus.
Table 2. Blood Lipids and Glucose Distribution in HCV-Infected Thal-
assemic Patients
Serum lipids and glucose Value
Serum TG, mg/dL 108 (100-116)
  >150 mg/dL, n (%) 19 (7)
LDL-C, mg/dL 51 (47-54)
  >200 mg/dL, n (%) 1 (0.4)
HDL-C 37 (35,038)
  M <40 mg/dL and F <50 mg/dL, n (%) 151 (72)
  Unavailable, n (%) 71 (25)
Cholesterol, mg/dL 99 (96-103)
Fasting glucose, mg/dL 104 (97-111)
Impaired glucose tolerance or diabetic, n (%) 48 (18)
BMI, kg/m
2 20 (20-21)
  BMI <25, n (%)  234 (94)
  BMI 25-30, n (%) 16 (6)
HCV, hepatitis C virus; TG, triglyceride; LDL-C, low-density lipo-
protein cholesterol; HDL-C, high-density lipoprotein cholesterol; M, 
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lipids and glucose levels. In our study, using Pearson’s cor-
relation coefficient, no statistically significant association was 
found between age, all blood lipids and glucose measurements. 
This was true even after adjustment of sex, viral markers and 
liver histologic findings. Serum ferritin was significantly as-
sociated with total cholesterol (p=0.001) and serum glucose 
level (p=0.02) (Fig. 2). Patients with diabetes mellitus had higher 
levels of serum ferritin than patients with normal fasting blood 
glucose (2,602 vs 1,877, p=0.01).
3. Impact of liver histology and viral markers on serum lip-
ids and glucose levels
Fig. 2 has presented distribution of various serum lipids and 
glucose according to ALT, serum HCV-RNA, and serum fer-
ritin. As it is visually obvious, there were no linear or curvular 
relation between any of serum lipids, glucose and HCV-RNA. 
Serum ferritin was only correlated with total cholesterol and 
serum glucose (p=0.001 and 0.02, respectively). 
Fig. 3 has depicted serum lipid and glucose levels according 
to stage of liver fibrosis, necroinflammatory activity, siderosis 
and infecting genotypes. It is visually evident from Fig. 3 that 
there were no significant differences in serum lipids and glucose 
levels. To evaluate the probable association between glucose 
intolerance and stage of liver disturbances chi-square test was 
used. No association was found between presence of insulin re-
sistance and stage and grade of liver disease and siderosis even 
after adjustment of sex.
Fig. 1. Distribution of blood lipids and glucose in 280 thalassemic 
patients with hepatitis C virus (HCV) infection. 
LDL, low-density lipoprotein cholesterol; HDL, high-density lipopro-
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DISCUSSION 
In this study, we investigated the distribution of blood lipids 
and glucose in a sample of Iranian beta-thalassemic major pa-
tients with chronic hepatitis C infection. To our knowledge, this 
work was the largest scale study of blood lipids among these 
patients. We found that nearly all of the participants had normal 
total cholesterol and LDL-C levels. In contrast, a considerable 
proportion of our patients had very low HDL-C levels. We also 
showed that there was no correlation between serum HCV-RNA 
copies, HCV genotypes, aminotransferase activities and blood 
lipids and glucose in thalassemic patients. Only serum ferritin 
correlated with total cholesterol and serum glucose (p=0.001 
and 0.02, respectively). 
1. Blood lipids and glucose in beta-thalassemic major pa-
tients with HCV infection
In our study, only one man had a higher than 200 mg/dL 
Fig. 2. Distribution of serum lipids and glucose according to hepatitis C virus (HCV) viral load, serum alanine aminotransferase (ALT), and serum 
ferritin. The correlations between serum ferritin and glucose and serum ferritin and total cholesterol are statistically significant. 
TG, triglyceride; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol.Alavian SM, et al: Lipid Profiles and Hepatitis C Viral Markers in HCV-Infected Thalassemic Patients  353
level of total cholesterol. A recent report from Azizi et al.
18 
which enrolled healthy children and adolescents from Iran has 
suggested that 16% of males and females at our patients’ ages 
had high total cholesterol. According to the previous studies, it 
is known that patients with beta-thalassemia major have lower 
total cholesterol levels compared with healthy individuals of 
the same age.
19 Based on the previous findings in thalassemic 
patients, we also observed low mean LDL-C levels in our sub-
jects. It is of interest that just three subjects had higher than 95 
mg/dL LDL-C levels. On the contrary, Azizi et al.
18 reported that 
17% of males and females with ages similar to our patients had 
above 130 mg/dL levels of LDL-C. Mean triglyceride was also 
low in our patients. Nineteen (7%) participants had triglyceride 
levels of higher than 150 mg/dL. In our study, thalassemic men 
had higher total cholesterol and LDL-C than thalassemic women 
(p=0.001 and 0.02). This is reciprocal to Azizi et al.’s findings 
in healthy children and adolescents
18 and others.
20 The majority 
of our participants had very low HDL-C levels. It has previously 
been described that low HDL-C is the most common type of 
dyslipidemia in Iranian healthy adults.
21 Hypocholesterolemia as 
well as low serum concentration of other lipids have been ex-
plained in various chronic anemic disorders such as thalassemia 
major, thalassemia intermedia and aplastic anemia.
22-24 Several 
mechanisms including plasma dilution resulting from anemia, 
increased cholesterol requirement associated with erythroid hy-
perplasia, macrophage system activation with cytokine release, 
Fig. 3. Distribution of the mean serum lipid and glucose levels according to hepatitis C virus (HCV) genotype, liver fibrosis, necroinflammatory 
activity, and liver iron deposition. None of the observed differences is statistically significant. 
TG, triglyceride; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; BMI, body mass index.354  Gut and Liver, Vol. 5, No. 3, September 2011
increased cholesterol uptake by the reticuloendotial system, and 
liver injury secondary to iron overload have been proposed.
25 In 
our study, we showed that chronic HCV infection does not alter 
pattern of serum lipids in thalassemic patients. 
Forty-eight subjects (18%) had previous established diagnosis 
of diabetes mellitus or had impaired glucose tolerance in our 
study. Ghoddusi et al.
26 and Hadaegh et al.
27 previously reported 
the prevalence of diabetes in Iranian general population to be 
around 11.0%.
26 Since we did not have control group, apply-
ing binomial test showed glucose intolerance in our study to be 
significantly higher than what was reported in Iranian general 
population (p=0.001). Serum total cholesterol and triglyceride 
were significantly higher in subjects with serum glucose >110 
mg/dL (p=0.02 and 0.006, respectively) which was similar to 
what Ghoddusi et al. have described in diabetic patients.
26,27 It 
is determined that thalassemic patients had significantly higher 
insulin resistance than healthy controls.
28 Dmochowski et al.
28 
have also explained that decreased hepatic extraction of insulin, 
but not higher excretion of pancreas beta-cells, is responsible 
for higher serum insulin level in thalassemic patients. Reduction 
in capability of liver to extract serum insulin as a result of in-
flammation and fibrosis caused by HCV infection and resultant 
higher serum insulin as well as low age of our subjects can ex-
plain our findings. We also indicated that distribution of mean 
serum fasting blood glucose in our participants is in border line 
of impaired tolerance. Hence, thalassemic patients with HCV 
infection may have very high rate of diabetes mellitus in 3rd or 
4th decades of their lives. We also showed that serum glucose is 
significantly correlated with serum iron, and more effective iron 
chelation therapy in these patients can avert or postpone devel-
opment of diabetes mellitus.
2. Implication of chronic HCV infection on serum lipids and 
glucose of thalassemic patients
In non-thalassemic HCV infected patients, it has previously 
been explained that there are association among metabolic 
syndrome, serum level of glucose, cholesterol, triglyceride and 
ALT levels as well as HCV viral load and genotype 1 and 2.
29,30 
Petit et al.
31 have also described a correlation between hypo-
betalipoproteinemia and liver fibrosis and viral load. Maeno et 
al.
32 by applying insulin homeostasis assessment model on 56 
non-thalassemic HCV infected subjects revealed that insulin 
resistance increased parallel with the progression of fibrosis. As 
presented in Figs. 2 and 3, in spite of enough sample size, we 
could not find any significant association of serum lipids and 
glucose with liver histologic findings, aminotransferase activity 
as well as serum HCV-RNA and HCV genotype in thalassemic 
patients with HCV infection.
32 Siagris et al.
3 have also revealed 
that steatosis in HCV infected thalassemic patients is lower than 
HCV infected patients.
We showed that in our thalassemic patients, serum glucose 
is not significantly associated with liver fibrosis, necroinflam-
matory and aminotransferase activities as well as virologic 
markers such as genotype and HCV-RNA. Genotype 2 had the 
highest mean blood glucose level. However, this difference was 
not significant applying one-way ANOVA. Serum glucose level 
had an increasing trend toward higher degrees of fibrosis and 
lower degrees of inflammation. This trend was not statistically 
significant (Fig. 3). Previously, it has been discovered that HCV 
infection in absence of liver cirrhosis can induce insulin resis-
tance and liver iron deposition and TNF-alpha was introduced 
as culprit mechanisms.
33,34 In our study on thalassemic patients, 
serum glucose was not different between various grades of liver 
siderosis, but it significantly correlated with serum ferritin. This 
implies that iron can cause peripheral insulin resistance besides 
hepatic injury reported in other studies.
33,35 To our knowledge, 
relation of serum glucose and insulin resistance with HCV viral 
markers is not well understood. In thalassemic patients we could 
not find any relation either. However, this issue needs more mo-
lecular and clinical investigations.
The present study revealed that HCV infected patients with 
beta-thalassemia major have blood lipid and lipoprotein levels 
within the normal range. An exception is the observed very low 
HDL -C levels. Viral markers, liver histologic findings as well 
as liver enzymes do not seem to play any role in determining 
serum cholesterol and triglyceride levels in thalassemic patients. 
Serum triglyceride, total cholesterol and serum iron can be in-
dependent risk factors of glucose intolerance in HCV infected 
thalassemic patients. 
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